Assessment of the radiation absorbed dose produced by 177Lu-iPSMA, 225Ac-iPSMA and 223RaCl2 to prostate cancer cell nuclei in a bone microenvironment model

• Published in: Applied radiation and isotopes Vol. 146; pp. 66 - 71
• Main Authors: Azorín-Vega, Erika, Rojas-Calderón, Eva, Ferro-Flores, Guillermina, Aranda-Lara, Liliana, Jiménez-Mancilla, Nallely, Nava-Cabrera, Miguel A.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.04.2019
• Subjects: Actinium-225; Lutetium-177; Prostate cancer; PSMA inhibitors; Theranostic radiopharmaceuticals; Actinium-225; Prostate cancer; Theranostic radiopharmaceuticals; PSMA inhibitors; Lutetium-177
• ISSN: 0969-8043; 1872-9800
• DOI: 10.1016/j.apradiso.2019.01.020

This research aimed to assess the radiation absorbed dose produced by 177Lu-iPSMA (177Lu-prostate specific membrane antigen inhibitor), 225Ac-iPSMA and 223RaCl2 to prostate cancer cell nuclei in a simplified model of bone by using an experimental in-vitro prostate cancer LNCaP cell biokinetic study and Monte Carlo simulation with the MCNPX code. Results showed that 225Ac-iPSMA releases a nine hundred-fold radiation dose greater than 177Lu-iPSMA and 14 times more than 223RaCl2 per unit of activity retained in bone. 225Ac-iPSMA could be the best option for treatment of bone metastases in prostate cancer. •225Ac-iPSMA produces doses to prostate cancer cells almost 3 orders of magnitude greater than 177Lu-iPSMA.•225Ac-iPSMA produces doses to prostate cancer cells in bone metastases 14 times greater than 223RaCl2.•225Ac-iPSMA could the best option for treatment of bone metastases in prostate cancer.